Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMET: Switching to Truvada + Efavirenz in HIV
NCT00224458Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2004
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Primary endpoints: Continued Viral Load Suppression at 24 weeks, CD4 Cell Count Changes at 24 weeks and 4 more. Started Sep 2004; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00224458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00224458.